For example, oestrogen-dependent tumours are treated with selective oestrogen receptor modulators (SERMs) or aromatase inhibitors3,4 and the recombinant antibody trastuzumab is tailored for action against HER2-positive breast cancers5,6. This evidence concerns the gene ERBB2 and neoplasm.